US Pharma MarketingClinical setbacks derailed what was once a potentially $2.2 billion deal that marked GSK's return to neuroscience.
GSK ends brain drug alliance with Alector
GSK ends brain drug alliance with Alector is a pharma and life sciences industry update from BioPharma Dive. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Source: BioPharma Dive